Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency
Rachael F. Grace(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Bertil Glader(Stanford University), Hua Yang(China Pharmaceutical University), F. Galactéros(Université Paris-Est Créteil), Hassan M. Yaish(Primary Children's Hospital), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Sujit Sheth(Columbia University Irving Medical Center), Bruce A. Silver(Johns Hopkins Hospital), D. Holmes Morton(Clinic for Special Children), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Yaddanapudi Ravindranath(The Barbara Ann Karmanos Cancer Institute), Kevin H.M. Kuo(University Health Network), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Ann Barbier(Agios Pharmaceuticals (United States)), Christian Rosé(Klinik und Poliklinik für Hautkrankheiten), Marvin B. Cohen(La Roche College), D. Mark Layton(Imperial College Healthcare NHS Trust), Lei Hua(Agios Pharmaceuticals (United States)), Charles Kung(Agios Pharmaceuticals (United States)), Eduard J. van Beers(Utrecht University)
Cited by 2
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
Ribosomal Protein L5 and L11 Mutations Are Associated with Cleft Palate and Abnormal Thumbs in Diamond-Blackfan Anemia Patients
|The American Journal of Human Genetics|2008|417